An Evaluation of Immune Responses to SARS-CoV-2 Infection or Vaccination
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Aditxt, Inc.
- 入组人数
- 403
- 试验地点
- 1
- 主要终点
- Laboratory assessment of SARS-CoV-2 antibody profiles
研究概览
简要总结
The overall purpose of this observational cohort study is to characterize COVID-specific immune responses to SARS-CoV-2 exposure or COVID vaccination in a real-world setting. Participants will be asked to provide blood samples (either a normal venous blood draw, a few drops of blood obtained with a small finger-stick device, or both), as well as saliva or nasal swab sample at a series of visits. Subjects will receive results of the testing that is approved for routine clinical use (i.e., their AditxtScore), while residual samples from each visit will be stored for future testing. These efforts will support ongoing AditxtScore test development and enhance the effectiveness of its interpretation - aiding efforts to maximize benefits of clinical laboratory testing in the pandemic response.
详细描述
- Background and Overview Aditxt, Inc, in collaboration with researchers at Stanford University, has laboratory-developed tests (LDTs) for simultaneously monitoring anti-SARS-COV2 antibodies (IgG, IgA, and IgM) directed against 3 different SARS-CoV-2 antigens (RBD, S1, and NP) as well as assessing SARS-CoV-2 neutralizing antibody activity.
These tests are currently being offered routinely to the public as the AditxtScoreTM at Aditxt's CLIA certified, CAP accredited clinical laboratory in Richmond, VA. Aditxt also performs these tests for research and development purposes at a facility in Mountain View, CA. The AditxtScore provides an ideal platform for real- world investigations of immune responses to SARS-CoV-2 exposure as well as to the COVID-19 vaccines.
The overall purpose of this observational cohort study is to characterize COVID-specific immune responses to SARS-CoV-2 exposure or COVID vaccination in a real-world setting. Participants will be asked to provide blood samples (either a normal venous blood draw, a few drops of blood obtained with a small finger-stick device, or both), as well as saliva or nasal swab sample at a series of visits. Subjects will receive results of the testing that is approved for routine clinical use (i.e., their AditxtScore), while residual samples from each visit will be stored for future testing. These efforts will support ongoing AditxtScore test development and enhance the effectiveness of its interpretation - aiding efforts to maximize benefits of clinical laboratory testing in the pandemic response. 2. Objectives • To characterize immune responses (e.g., magnitude/strength and temporal dynamics of antibody generation, class switching, and antibody persistence) following exposure to the SARS-CoV-2 virus or COVID-19 vaccination.
• To investigate between group (eg vaccine vs. natural exposure) and within group (i.e., individual variation) differences in immune responses.
• To determine the relationship between AditxtScore components and neutralizing antibody activity and other potential correlates of protection, and to describe possible clinical correlates of immune response characteristics.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willingness to participate
- •18 years and older
排除标准
- •Refusal or inability to provide informed consent
结局指标
主要结局
Laboratory assessment of SARS-CoV-2 antibody profiles
时间窗: 2 years
Antibody profiles consist of quantitative determination of IgG, IgM, and IgA levels to the SARs-CoV-2 spike protein (S), receptor binding domain (RBD), and nucleocapsid protein (NP) by flow cytometry. Also, Neutralizing Antibody (NAb) concentrations were determined with a novel flow cytometry based competitive inhibition assay for the measurement of total neutralizing antibodies to different variants of SARS-CoV-2.
次要结局
未报告次要终点
